Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_203_16
Obesity and Breast Cancer: Association of Serum Adiponectin, Leptin, and Adiponectin–Leptin Ratio as Risk Biomarkers
Financial support and sponsorship Nil.
Abstract
Introduction: Obesity has been associated with the development of breast cancer. The objectives were to study the association of serum adiponectin, serum leptin, and adiponectin–leptin ratio (ALR) in patients with breast cancer and matched controls, and to study their relationship with the various clinicopathological characteristics of breast cancer. Materials and Methods: A prospective, hospital-based case–control study was conducted on 40 patients with a first-confirmed histopathology diagnosis of breast cancer and 40 controls comprising individuals without a history of cancer simultaneously recruited from the health examination clinics during the same study period. Serum adiponectin and leptin concentrations were measured in a single run using commercially available kits (Human ADP/Acrp30 [adiponectin] enzyme-linked immune-sorbent assay [ELISA] kit and Human Leptin ELISA kit, Elabscience Biotechnology Co., Ltd) according to the manufacturer's instructions. Results:: Serum adiponectin levels were reduced significantly in breast cancer patients, in comparison to controls (P = 0.04), while serum leptin levels were increased significantly in breast cancer patients, in comparison to controls (P = 0.03). ALR was significantly lower in breast cancer cases, in comparison to controls (P = 0.05). There was no correlation between receptor status (estrogen receptor, progesterone receptor, Her2/neu), aggressiveness of disease in terms of tumor size, nodal metastases, stage, tumor grade, and serum adiponectin levels, leptin levels, or ALR. Body mass index was negatively correlated with serum adiponectin levels and ALR (r = 0.33, P = 0.03; r = 0.39, P = 0.01, respectively) and positively correlated with serum leptin levels (r = 0.34, P = 0.02). Conclusion: In summary, our results suggest that low serum adiponectin levels, ALR, and high serum leptin levels are associated with breast cancer.
Publication History
Article published online:
17 June 2021
© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: The estrogen connection. Endocrinology 2009; 150: 2537-42
- 2 Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer-Mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10: 455-65
- 3 Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: A systematic review. Br J Cancer 2006; 94: 1221-5
- 4 Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise. Obes Rev 2015; 16: 473-87
- 5 Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME. Targeting the adiponectin: Leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 2009; 1: 329-57
- 6 Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A. et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014; 25: 1901-14
- 7 Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011; 47: 33-43
- 8 Okumura M, Yamamoto M, Sakuma H, Kojima T, Maruyama T, Okumura M. et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: Reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta 2002; 1592: 107-16
- 9 Wang Y, Lam KS, Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res 2007; 17: 280-2
- 10 Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F. et al. Involvement of adiponectin and leptin in breast cancer: Clinical and in vitro studies. Endocr Relat Cancer 2009; 16: 1197-210
- 11 Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett 2008; 582: 1719-24
- 12 Rahal OM, Simmen RC. Paracrine-acting adiponectin promotes mammary epithelial differentiation and synergizes with genistein to enhance transcriptional response to estrogen receptor β signaling. Endocrinology 2011; 152: 3409-21
- 13 Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009; 20: 193-201
- 14 Ryan AS, Berman DM, Nicklas BJ, Sinha M, Gingerich RL, Meneilly GS. et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 2003; 26: 2383-8
- 15 Grossmann ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, Dogan S. et al. Obesity and breast cancer: Status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010; 29: 641-53
- 16 Aguilar-Salinas CA, García EG, Robles L, Riaño D, Ruiz-Gomez DG, García-Ulloa AC. et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008; 93: 4057-9
- 17 Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM. et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102-7
- 18 Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003; 9: 5699-704
- 19 Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY. et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006; 237: 109-14
- 20 Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS. et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. Breast Cancer Res 2011; 13: R34
- 21 Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC. et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 2007; 14: 669-77
- 22 Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS. et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 2007; 92: 1510-6
- 23 Cust AE, Stocks T, Lukanova A, Lundin E, Hallmans G, Kaaks R. et al. The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: A prospective study. Breast Cancer Res Treat 2009; 113: 567-76
- 24 Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: Stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003; 49: 650-2
- 25 Weiss EP, Racette SB, Villareal DT, Fontana L, Steger-May K, Schechtman KB. et al. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: A randomized controlled trial. Am J Clin Nutr 2006; 48: 1033-42
- 26 Christou NV, Lieberman M, Sampalis F, Sampalis JS. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis 2008; 4: 691-5
- 27 Westerink J, Visseren FL. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011; 10: 13
- 28 Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes 2010; 1: 116-28
- 29 Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA. et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 2009; 296: E480-9
- 30 Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J 2007; 54: 413-5
- 31 Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, Jungbauer A, Wolzt M. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008; 38: 820-6
- 32 Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J. et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. Int Heart J 2009; 50: 501-12